KPTI
Karyopharm Therapeutics Inc.6.33
-0.38-5.66%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A reinforces SENTRY confidence
Q&A largely reaffirmed prepared remarks, with management confidently fielding queries on SENTRY myelofibrosis trial details ahead of March readout. They highlighted Phase I data favoring 60mg selinexor over 40mg for efficacy like SVR and TSS, with higher exposures and modest safety gaps. Novartis' MF plans validate unmet need but leave Karyopharm ahead on US filing timing. Eltenexor eyed for MPN expansion post-positive data, with IP to mid-2034 plus extensions possible. Patient baselines milder than Phase I, yet subgroup consistency expected; KOLs prioritize SVR. No new blinded safety updates. Data defines next steps.
Key Stats
Market Cap
107.93MP/E (TTM)
-Basic EPS (TTM)
-14.70Dividend Yield
0%Recent Filings
8-K
Defers debt payments on $25M raise
Karyopharm signed a Second Amendment to its Credit Agreement and Forbearance Agreement on February 27, 2026, deferring principal and interest payments to September 2026 while holding minimum liquidity at $10.0 million through October 10, 2026—if it raises $25.0 million in equity by June 10. Lenders and noteholders fully back the deal. Cash runway stretches past Q2 2026 and Phase 3 XPORT-EC-042 data in mid-2026. Forbearance isn't a default waiver.
8-K
Stockholders approve share increase
Karyopharm Therapeutics stockholders approved on February 18, 2026, an amendment boosting authorized shares from 58.3M to 111M total and common stock from 53.3M to 106M, with 9.4M votes for versus 3.2M against. The company filed the certificate that day in Delaware. Flexibility unlocked. Adjournment proved unnecessary amid strong quorum.
10-K
FY2025 results
Karyopharm posted $146.1M total revenue for FY2025 ended December 31, 2025, edging up from $145.2M in 2024 on steady XPOVIO net product sales of $114.9M (up 2% y/y, driven by higher net pricing despite steady gross-to-net trends). Yet net losses exploded to $196.0M from $76.4M, fueled by a $62.4M debt extinguishment charge from October 2025 Financing Transactions that exchanged maturing notes for equity, new term loans, and convertibles while deferring near-term payments. Q4 saw intensified cash burn relief via $52M lower operating outflows (to $75M annual), but liquidity dwindles to $63.7M amid $235M total debt and going concern warnings funding only to Q2 2026. Cash stays king. Clinical catalysts loom: SENTRY myelofibrosis topline March 2026.
8-K
Q4 results, trial catalysts
Karyopharm reported full-year 2025 total revenue of $146M, with U.S. XPOVIO net product revenue at $115M, up slightly from 2024 despite fierce multiple myeloma competition. Phase 3 SENTRY myelofibrosis top-line data looms in March 2026; endometrial cancer readout mid-year. Cash funds operations to Q2 2026. Catalysts ahead.
8-K
Preliminary 2025 revenue, trial catalysts
APTOF
Aptose Biosciences. Inc.
1.60-0.04
COEP
Coeptis Therapeutics Holdings,
14.43-0.66
EXEL
Exelixis, Inc.
41.60+0.22
IOVA
Iovance Biotherapeutics, Inc.
2.25+0.09
KROS
Keros Therapeutics, Inc.
21.53+0.30
KURA
Kura Oncology, Inc.
10.63+0.07
LGND
Ligand Pharmaceuticals Incorpor
192.63-0.25
LPTX
Leap Therapeutics, Inc.
2.05+1.61
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
SRPT
Sarepta Therapeutics, Inc.
22.31+0.76